title: Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.
abstract: OBJECTIVE
  Two large, randomized, placebo-controlled trials (IRESSA NSCLC Trial Assessing Combination Therapy; INTACT 1 and 2) in non-small-cell lung cancer (NSCLC) failed to show survival benefit for gefitinib (IRESSA) in combination with first-line platinum-based chemotherapy. Epidermal growth factor receptor (EGFR) staining was assessed retrospectively in relation to survival response to gefitinib in combination with chemotherapy.
  
  
  METHODS
  Tumor biopsies obtained prior to start of therapy were assessed by immunohistochemistry for EGFR using the Dako EGFR pharmDx assay (Dako, Denmark). Analyses were stratified by trial and performed independently for patients randomized to placebo and gefitinib as well as for both treatment groups combined. A restricted backwards elimination Cox regression analysis was conducted to identify independent EGFR factors that were statistically significant (P < 0.10), and these were also tested for treatment interaction to assess if they served as predictive factors.
  
  
  RESULTS
  Analyses found two statistically significant EGFR-based prognostic factors representing growth pattern and percent membrane staining in patients treated with gefitinib (P = 0.0023), placebo (P = 0.0128), and both combined (P < 0.0001). The prognostic effect was independent of other known prognostic factors. There was no predictive effect of either the growth pattern or membrane staining variable.
  
  
  CONCLUSIONS
  While some previous studies indicate that higher EGFR expression correlates with poor survival, our analyses provide statistically significant evidence that the combination of EGFR expression and growth pattern is a strong prognostic indicator for improved survival within this setting. The effects of membrane staining and growth pattern are still significant when adjusting for mutation.
authors.affiliation: Free University Medical Center, Amsterdam, The Netherlands. giacconeg@mail.nih.gov
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Giaccone
authors.forename: Renee B
authors.initials: RB
authors.lastname: Iacona
authors.forename: Abderrahim
authors.initials: A
authors.lastname: Fandi
authors.forename: Mette
authors.initials: M
authors.lastname: Janas
authors.forename: Judith S
authors.initials: JS
authors.lastname: Ochs
authors.forename: Roy S
authors.initials: RS
authors.lastname: Herbst
authors.forename: David H
authors.initials: DH
authors.lastname: Johnson
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001706:Biopsy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D066246:ErbB Receptors / Q000235:genetics* / Q000378:metabolism; D000077156:Gefitinib; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D010919:Placebos; D017671:Platinum Compounds / Q000008:administration & dosage; D011379:Prognosis; D011799:Quinazolines / Q000627:therapeutic use*; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D010919:Placebos; D017671:Platinum Compounds; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib
references.citation: N Engl J Med. 2005 Jul 14;353(2):123-32
references.pmid: 16014882
references.citation: Anticancer Res. 1997 Jul-Aug;17(4A):2769-73
references.pmid: 9252713
references.citation: J Clin Oncol. 2005 Sep 1;23(25):5900-9
references.pmid: 16043828
references.citation: Eur J Surg Oncol. 2003 Mar;29(2):178-84
references.pmid: 12633562
references.citation: J Clin Oncol. 2007 Apr 20;25(12):1545-52
references.pmid: 17442998
references.citation: J Clin Oncol. 2006 Nov 1;24(31):5034-42
references.pmid: 17075123
references.citation: J Clin Oncol. 2005 Nov 1;23(31):8081-92
references.pmid: 16204011
references.citation: J Clin Oncol. 2004 Mar 1;22(5):785-94
references.pmid: 14990633
references.citation: Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232
references.pmid: 7612182
references.citation: Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37
references.pmid: 16257339
references.citation: J Postgrad Med. 2001 Jul-Sep;47(3):199-203
references.pmid: 11832625
references.citation: Semin Oncol. 2002 Oct;29(5 Suppl 14):45-54
references.pmid: 12422313
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: J Pathol. 2005 Mar;205(4):491-7
references.pmid: 15685591
references.citation: J Natl Cancer Inst. 2005 May 4;97(9):643-55
references.pmid: 15870435
references.citation: Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15
references.pmid: 11597399
references.citation: Br J Cancer. 2003 Oct 6;89(7):1266-9
references.pmid: 14520458
references.citation: Science. 2004 Aug 20;305(5687):1163-7
references.pmid: 15284455
references.citation: Science. 1989 May 12;244(4905):707-12
references.pmid: 2470152
references.citation: Anticancer Res. 2005 May-Jun;25(3B):1901-7
references.pmid: 16158924
references.citation: Br J Cancer. 1998 Feb;77(4):663-9
references.pmid: 9484827
references.citation: Br J Cancer. 1993 Jul;68(1):162-5
references.pmid: 8391303
references.citation: J Natl Cancer Inst. 2004 Aug 4;96(15):1133-41
references.pmid: 15292385
references.citation: J Clin Oncol. 2005 Sep 1;23(25):5892-9
references.pmid: 16043829
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: Oncol Rep. 2000 May-Jun;7(3):603-7
references.pmid: 10767376
references.citation: Clin Cancer Res. 2001 Jul;7(7):1850-5
references.pmid: 11448895
references.citation: Pharmacol Ther. 1999 May-Jun;82(2-3):241-50
references.pmid: 10454201
references.citation: Biometrics. 1975 Mar;31(1):103-15
references.pmid: 1100130
references.citation: Eur Respir J. 2002 Oct;20(4):975-81
references.pmid: 12412692
references.citation: N Engl J Med. 2005 Jul 14;353(2):133-44
references.pmid: 16014883
references.citation: J Clin Oncol. 2004 Mar 1;22(5):777-84
references.pmid: 14990632